Inclusion Criteria:  Capable of giving signed informed consent. Male and female patients ≥18 years of age Body weight of >40 kg Diagnosis of chronic, stable plaque-type psoriasis. If the patient is diagnosed with psoriasis arthritis, the arthritis should be stable. Moderate-to-severe plaque-type psoriasis as defined by PASI ≥12, BSA ≥10%, and IGA ≥3. Candidate for systemic antipsoriatic treatment or phototherapy.  Exclusion Criteria:  Therapy-resistant psoriasis Unstable psoriasis or psoriatic arthritis with acute deterioration within 4 weeks of the Screening visit. History of allergy or hypersensitivity to any component of the study treatment. Active infection (eg, bacteria, viral, fungal) requiring treatment with systemic antibiotics within 4 weeks of the Screening visit. Malignancy or history of malignancy except for treated (ie, cured) basal cell skin carcinomas.